Valuation: SourcingLink.net, Inc.

Market Cap 2.05M 1.8M 1.66M 1.55M 2.91M 193M 2.97M 19.91M 7.7M 95.53M 7.69M 7.53M 331M P/E 2003 *
-
P/E 2004 -
Enterprise Value 2.05M 1.8M 1.66M 1.55M 2.91M 193M 2.97M 19.91M 7.7M 95.53M 7.69M 7.53M 331M EV / Sales 2003
-
EV / Sales 2004 -
Free-Float
100%
Yield 2003 *
-
Yield 2004 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+9.50% - - 2.05M
+7.13%+9.97%+55.80%+163.38% 1,077B
+3.99%+11.50%+67.09%+56.27% 613B
+4.20%+17.03%+38.97%+91.19% 448B
+0.33%+4.85%+28.17%+22.04% 332B
-0.43%+7.21%+40.79%+26.81% 293B
-0.78%+4.17%+30.29%+40.58% 286B
-1.61%+4.15%-28.94%-41.43% 215B
+1.56%+6.14%+29.30%+61.91% 193B
+3.26%+3.33%+15.55%+67.87% 159B
Average -0.26%+8.48%+30.78%+54.29% 401.79B
Weighted average by Cap. +0.20%+9.65%+41.64%+80.74%

Financials

2003 2004
Net sales 3.28M 2.88M 2.65M 2.48M 4.65M 309M 4.75M 31.86M 12.33M 153M 12.32M 12.05M 530M 1.18M 1.04M 954K 894K 1.68M 111M 1.71M 11.47M 4.44M 55.06M 4.43M 4.34M 191M
Net income -1.52M -1.33M -1.23M -1.15M -2.16M -143M -2.2M -14.77M -5.71M -70.86M -5.71M -5.58M -246M -1.56M -1.37M -1.26M -1.18M -2.22M -148M -2.27M -15.2M -5.88M -72.96M -5.88M -5.75M -253M
Net Debt -1.35M -1.18M -1.09M -1.02M -1.91M -127M -1.95M -13.08M -5.06M -62.75M -5.05M -4.94M -218M 17K 14.91K 13.74K 12.86K 24.12K 1.6M 24.62K 165K 63.9K 793K 63.84K 62.44K 2.75M
Logo SourcingLink.net, Inc.
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
Employees
-